News

News

GLP-1 drugs increase healthcare costs for obese patients

28 Oct 2024


Despite significant weight-loss benefits due to drugs like Novo Nordisk’s Wegovy, an analysis of US health insurance claims reveals that these medications may drive healthcare costs higher rather than reducing obesity-related expenses, reported Reuters (25 Oct 2024).
“According to data from Prime Therapeutics, a pharmacy benefits manager, US patients’ average annual medical expenses rose by 46% within two years of starting GLP-1 medications like Wegovy.

[BACK TO NEWS]